Anticoagulation Type and Early Recurrence in Cardioembolic Stroke
暂无分享,去创建一个
K. Furie | N. Henninger | A. D. de Havenon | A. Nouh | S. Yaghi | S. Keyrouz | J. Giles | A. Lord | Muhib Khan | Brian C. Mac Grory | Tushar Trivedi | N. Cheng | Iman Moeini-naghani | E. Mistry | E. Scher | Ava L. Liberman | Angela Liu | M. Nagy | A. Kaushal | Idrees Azher | Hiba Fakhri | S. Asad | Heather Martin | Jose T Tan | Manivannan Veerasamy | C. Esenwa | Khadean Moncrieffe | Mithilesh Siddu | C. L. Leon Guerrero | Kiersten Brown Espaillat | H. Pasupuleti | Ashutosh Kaushal | A. Liberman | James A. Giles | B. M. Mac Grory | Natalie T. Cheng | Charles C. Esenwa | Muhib Khan | Muhammad Nagy
[1] Eric E. Smith,et al. Clinical Effectiveness of Direct Oral Anticoagulants vs Warfarin in Older Patients With Atrial Fibrillation and Ischemic Stroke: Findings From the Patient-Centered Research Into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) Study. , 2019, JAMA neurology.
[2] K. Furie,et al. Anticoagulation After Stroke in Patients With Atrial Fibrillation. , 2019, Stroke.
[3] D. Werring,et al. Direct oral anticoagulants versus vitamin K antagonists after recent ischemic stroke in patients with atrial fibrillation , 2019, Annals of neurology.
[4] S. Warach,et al. Timing of anticoagulation after recent ischaemic stroke in patients with atrial fibrillation , 2019, The Lancet Neurology.
[5] Carol Coupland,et al. Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care , 2018, British Medical Journal.
[6] S. Mayer,et al. Treatment and Outcome of Hemorrhagic Transformation After Intravenous Alteplase in Acute Ischemic Stroke: A Scientific Statement for Healthcare Professionals From the American Heart Association/American Stroke Association , 2017, Stroke.
[7] K. Furie,et al. Early Recurrence and Major Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation Treated With Non–Vitamin‐K Oral Anticoagulants (RAF‐NOACs) Study , 2017, Journal of the American Heart Association.
[8] Deborah M Caldwell,et al. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis , 2017, BMJ.
[9] Tyler J. VanderWeele,et al. Sensitivity Analysis in Observational Research: Introducing the E-Value , 2017, Annals of Internal Medicine.
[10] R. Passman. Time in Therapeutic Range in Warfarin-Treated Patients: Is Very Good Good Enough? , 2016, JAMA.
[11] D. McManus,et al. Atrial Fibrillation Is Associated With a Worse 90-Day Outcome Than Other Cardioembolic Stroke Subtypes , 2016, Stroke.
[12] W. Ageno,et al. Early Recurrence and Cerebral Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation: Effect of Anticoagulation and Its Timing The RAF Study , 2015, Stroke.
[13] B. Gersh,et al. Use and Outcomes Associated With Bridging During Anticoagulation Interruptions in Patients With Atrial Fibrillation , 2015, Circulation.
[14] Alexander Parkhomenko,et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials , 2014, The Lancet.
[15] V. Chair,et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. , 2014, Stroke.
[16] C. Kase,et al. Factors influencing haemorrhagic transformation in ischaemic stroke , 2013, The Lancet Neurology.
[17] P. Sandercock,et al. Targeted use of heparin, heparinoids, or low-molecular-weight heparin to improve outcome after acute ischaemic stroke: an individual patient data meta-analysis of randomised controlled trials , 2013, The Lancet Neurology.
[18] Paolo Prandoni,et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.
[19] D. Berlowitz,et al. Risk-Adjusted Percent Time in Therapeutic Range as a Quality Indicator for Outpatient Oral Anticoagulation: Results of the Veterans Affairs Study To Improve Anticoagulation (VARIA) , 2011, Circulation. Cardiovascular quality and outcomes.
[20] D. Leys,et al. Asymptomatic Hemorrhagic Transformation of Infarction and Its Relationship With Functional Outcome and Stroke Subtype: Assessment From the Tinzaparin in Acute Ischaemic Stroke Trial , 2010, Stroke.
[21] M. Mazzola,et al. Frequency and Determinants for Hemorrhagic Transformation of Cerebral Infarction , 2009, Neuroepidemiology.
[22] J. Grotta,et al. Anticoagulation after cardioembolic stroke: to bridge or not to bridge? , 2008, Archives of neurology.
[23] J. Arenillas,et al. Timing of Spontaneous Recanalization and Risk of Hemorrhagic Transformation in Acute Cardioembolic Stroke , 2001, Stroke.
[24] E. Berge,et al. Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study , 2000, The Lancet.
[25] E. Berge,et al. Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial. , 2000, Lancet.
[26] A. Arboix,et al. Clinical Predictors of Early Embolic Recurrence in Presumed Cardioembolic Stroke , 1998, Cerebrovascular Diseases.
[27] Peter Sandercock,et al. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke , 1997, The Lancet.
[28] J. Hirsh,et al. Comparison of 5-mg and 10-mg Loading Doses in Initiation of Warfarin Therapy , 1997, Annals of Internal Medicine.
[30] M. D. Freedman. Oral Anticoagulants: Pharmacodynamics, Clinical Indications and Adverse Effects , 1992, Journal of clinical pharmacology.